HRP20171697T1 - Varijanta hiv gp-120 - Google Patents

Varijanta hiv gp-120 Download PDF

Info

Publication number
HRP20171697T1
HRP20171697T1 HRP20171697TT HRP20171697T HRP20171697T1 HR P20171697 T1 HRP20171697 T1 HR P20171697T1 HR P20171697T T HRP20171697T T HR P20171697TT HR P20171697 T HRP20171697 T HR P20171697T HR P20171697 T1 HRP20171697 T1 HR P20171697T1
Authority
HR
Croatia
Prior art keywords
polypeptide
fact
polynucleotide
sample
neutralizing antibodies
Prior art date
Application number
HRP20171697TT
Other languages
English (en)
Inventor
María Eloísa Yuste Herranz
Víctor SÁNCHEZ MERINO
Carolina Ferreira
Original Assignee
Laboratorios Del Dr. Esteve, S.A.
Fundació Privada Institut De Recerca De La Sida-Caixa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Del Dr. Esteve, S.A., Fundació Privada Institut De Recerca De La Sida-Caixa filed Critical Laboratorios Del Dr. Esteve, S.A.
Publication of HRP20171697T1 publication Critical patent/HRP20171697T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/162—HIV-1, HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, DC4-Binding site
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Claims (13)

1. Polipeptid koji može izazvati stvaranje neutralizirajućih protutijela protiv virusa koji sadrži varijantu HIV-1 gp120 ili njegov imunogeni fragment, naznačen time što polipeptid ili njegov imunogeni fragment sadrži slijed sa SEQ ID NO:4.
2. Protutijelo, naznačeno time što se specifično veže na polipeptid u skladu s patentnim zahtjevom 1.
3. Polinukleotid, naznačen time što kodira polipeptid u skladu s patentnim zahtjevom 1.
4. Polinukleotid u skladu s patentnim zahtjevom 3, naznačen time što ima slijed sa SEQ ID NO:3.
5. Ekspresijski vektor, naznačen time što sadrži polinukleotid u skladu s patentnim zahtjevom 4.
6. Stanica domaćin, naznačena time što sadrži polipeptid u skladu s patentnim zahtjevom 1, polinukleotid u skladu s patentnim zahtjevom 3 ili ekspresijski vektor u skladu s patentnim zahtjevom 5.
7. Imunogeni pripravak ili cjepivo, naznačeni time što sadrže polipeptid u skladu s patentnim zahtjevom 1, polinukleotid u skladu s patentnim zahtjevom 3 ili ekspresijski vektor u skladu s patentnim zahtjevom 5.
8. Polipeptid u skladu s patentnim zahtjevom 1, polinukleotid u skladu s patentnim zahtjevom 3, ekspresijski vektor u skladu s patentnim zahtjevom 5 ili imunogeni pripravak ili cjepivo u skladu s patentnim zahtjevom 7, naznačeni time što su namijenjeni upotrebi u medicini.
9. Polipeptid u skladu s patentnim zahtjevom 1, polinukleotid u skladu s patentnim zahtjevom 3, ekspresijski vektor u skladu s patentnim zahtjevom 5 ili imunogeni pripravak ili cjepivo u skladu s patentnim zahtjevom 7, naznačeni time što su namijenjeni upotrebi u sprječavanju bolesti uzrokovane infekcijom HIV-om.
10. Postupak detektiranja u uzorku neutralizirajućih protutijela specifičnih za dani patogeni, naznačen time što obuhvaća: (i) stavljanje u kontakt navedenog uzorka s polipeptidom u skladu s patentnim zahtjevom 1 i (ii) detektiranje nastajanja imunosnog kompleksa između navedenog polipeptida i navedenih neutralizirajućih protutijela.
11. Postupak detektiranja in vitro neutralizirajućeg protutijela kao odgovora na virusnu infekciju kod subjekta, naznačen time što obuhvaća detektiranje u uzorku iz navedenog subjekta prisutnosti neutralizirajućih protutijela postupkom u skladu s patentnim zahtjevom 10, gdje prisutnost neutralizirajućih protutijela u navedenom uzorku za razliku od kontrolnog subjekta ukazuju na neutralizirajuće protutijelo kao odgovor na virusnu infekciju kod navedenog subjekta.
12. Postupak u skladu s patentnim zahtjevima 10 ili 11, naznačen time što je virus HIV.
13. Postupak u skladu s patentnim zahtjevom 12, naznačen time što je uzorak dobiven iz pacijenta zaraženog virusom HIV-1 ili, što je uzorak dobiven iz primatelja cjepiva protiv AIDS-a.
HRP20171697TT 2011-02-25 2017-11-06 Varijanta hiv gp-120 HRP20171697T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161446595P 2011-02-25 2011-02-25
EP11382051A EP2492279A1 (en) 2011-02-25 2011-02-25 Rapid immunogen selection method using lentiviral display
PCT/EP2012/053185 WO2012113921A1 (en) 2011-02-25 2012-02-24 Rapid selection method for hiv gp-120 variants
EP12705689.3A EP2678351B1 (en) 2011-02-25 2012-02-24 Hiv gp-120 variant

Publications (1)

Publication Number Publication Date
HRP20171697T1 true HRP20171697T1 (hr) 2018-01-26

Family

ID=44246584

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20171697TT HRP20171697T1 (hr) 2011-02-25 2017-11-06 Varijanta hiv gp-120

Country Status (22)

Country Link
US (1) US9605030B2 (hr)
EP (2) EP2492279A1 (hr)
JP (1) JP6140614B2 (hr)
KR (1) KR20140025356A (hr)
CN (1) CN103459410B (hr)
AU (1) AU2012219418C1 (hr)
CA (1) CA2827967A1 (hr)
CY (1) CY1119638T1 (hr)
DK (1) DK2678351T3 (hr)
ES (1) ES2651124T3 (hr)
HR (1) HRP20171697T1 (hr)
HU (1) HUE035432T2 (hr)
IL (1) IL228094A0 (hr)
LT (1) LT2678351T (hr)
ME (1) ME03045B (hr)
MX (1) MX348459B (hr)
PL (1) PL2678351T3 (hr)
PT (1) PT2678351T (hr)
RS (1) RS56707B1 (hr)
RU (1) RU2603732C2 (hr)
SI (1) SI2678351T1 (hr)
WO (1) WO2012113921A1 (hr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2492279A1 (en) 2011-02-25 2012-08-29 Laboratorios Del. Dr. Esteve, S.A. Rapid immunogen selection method using lentiviral display
EP2698377A1 (en) * 2012-08-17 2014-02-19 Laboratorios Del. Dr. Esteve, S.A. Enhanced rapid immunogen selection method for HIV gp120 variants
CN104697830B (zh) * 2015-02-10 2018-06-15 深圳市新产业生物医学工程股份有限公司 用于hiv检测的酸性处理剂、样本预处理方法、试剂盒及检测方法
CN107988428B (zh) * 2017-11-10 2021-04-06 杭州众测生物科技有限公司 虾虹彩病毒(siv)的raa恒温荧光检测方法及试剂
JP2019153618A (ja) * 2018-02-28 2019-09-12 株式会社ジャパンディスプレイ 光センサ装置

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
JPS604422B2 (ja) 1976-10-07 1985-02-04 持田製薬株式会社 抗原の定量方法
IL51667A (en) 1977-03-16 1979-10-31 Miles Yeda Ltd Immunoassay for the determination of a hapten
NL7807532A (nl) 1978-07-13 1980-01-15 Akzo Nv Metaal-immunotest.
NL8000173A (nl) 1980-01-11 1981-08-03 Akzo Nv Toepassing van in water dispergeerbare, hydrofobe kleurstoffen als label in immunochemische testen.
US4401764A (en) 1980-02-07 1983-08-30 Technicon Instruments Corporation Immunoassays employing labeled reagent and a conjugate having two binding sites
GB2084317B (en) 1980-09-30 1984-01-18 Erba Farmitalia Antigen-linked competitive enzymeimmunoassay
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4661444A (en) 1984-03-29 1987-04-28 Ortho Diagnostic Systems Inc. Homogeneous immunoassays employing double antibody conjugates comprising anti-idiotype antibody
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5100792A (en) 1984-11-13 1992-03-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4746631A (en) 1985-05-09 1988-05-24 Ultra Diagnostics Corporation Immunoassay method, device, and test kit
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5585279A (en) 1986-01-23 1996-12-17 Davidson; Robert S. Time-resolved luminescence binding assays using a fluorescent transition metal label other than ruthenium
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
EP0310361A3 (en) 1987-09-30 1989-05-24 Beckman Instruments, Inc. Tridentate conjugate and method of use thereof
DE3855134T2 (de) 1987-11-13 1996-10-02 Hermann Katinger Monoklonale menschliche antikörper gegen hiv-i
US5244797B1 (en) 1988-01-13 1998-08-25 Life Technologies Inc Cloned genes encoding reverse transcriptase lacking rnase h activity
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
AU6523590A (en) 1989-09-22 1991-04-18 Idec Pharmaceuticals Corporation Novel peptides associated with the cd4 binding region of gp120 and their methods of use
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991017764A1 (en) * 1990-05-16 1991-11-28 Dana Farber Cancer Institute Immunogenic peptides, antibodies and uses thereof relating to cd4 receptor binding
ES2089057T3 (es) 1990-07-18 1996-10-01 Abbott Lab Un reactivo sustituto de un analito para uso en metodos de ensayo de fijacion especifica, dispositivos y kits.
US5783415A (en) 1991-03-29 1998-07-21 Genentech, Inc. Method of producing an IL-8 receptor polypeptide
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
EP0671926B1 (en) 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunomodulatory peptides
EP0675904B1 (en) 1992-09-30 2003-03-05 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
US5359681A (en) 1993-01-11 1994-10-25 University Of Washington Fiber optic sensor and methods and apparatus relating thereto
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
US5563036A (en) 1994-04-29 1996-10-08 Tularik, Inc. Transcription factor-DNA binding assay
AU2587795A (en) 1994-05-20 1995-12-18 Tularik Inc. Epstein-barr virus transcription factor binding assay
US5747352A (en) 1994-05-23 1998-05-05 Beckman Instruments, Inc. Reagents and methods for the rapid and quantitative assay of pharmacological agents
US5691147A (en) 1994-06-02 1997-11-25 Mitotix, Inc. CDK4 binding assay
US5627080A (en) 1994-07-29 1997-05-06 Beckman Instruments, Inc. Detergent-facilitated immunoassay for the rapid and quantitative assay of pharmacological agents
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
MX9708008A (es) 1995-04-19 1998-03-31 Polymun Scient Immunbio Forsch Anticuerpos monoclonales contra vih-1 y vacunas hechas de los mismos.
US5698411A (en) 1995-05-18 1997-12-16 Coulter Corporation Method for determining activity of enzymes in metabolically active whole cells
US5976822A (en) 1995-05-18 1999-11-02 Coulter International Corp. Method and reagent for monitoring apoptosis and distinguishing apoptosis from necrosis
US5759781A (en) 1995-12-22 1998-06-02 Yale University Multiparametric fluorescence in situ hybridization
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US5876935A (en) 1997-01-08 1999-03-02 Dade Behring Inc. Luminescent specific binding assay
EP2251347A3 (en) 1997-04-22 2011-02-23 Life Technologies Corporation Methods for the production of ASLV reverse transcriptases composed of multiple subunits
US6924112B1 (en) 1997-12-04 2005-08-02 Biomethodes S.A.R.L. Cloning method by multiple-digestion, vectors for implementing same and applications
US6762031B2 (en) * 2000-06-16 2004-07-13 University Of Medicine And Dentistry Of New Jersey Targeting viral vectors to specific cells
CA2419822C (en) * 2000-08-14 2011-02-08 Gary J. Nabel Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization
CN1339319A (zh) 2000-08-18 2002-03-13 清华大学 一种治疗艾滋病的药物及其制备方法
US20070111201A1 (en) 2001-04-30 2007-05-17 Benjamin Doranz Reverse transfection of cell arrays for structural and functional analyses of proteins
RU2237065C2 (ru) * 2002-10-03 2004-09-27 Государственный научный центр вирусологии и биотехнологии "Вектор" Иммуногенная библиотека химерных пептидов, мимикрирующая генетическое многообразие гипервариабельного района v3 белка оболочки gp120 вируса иммунодефицита человека
CA2539325C (en) * 2003-09-17 2016-03-22 Duke University Consensus/ancestral immunogens
WO2009117661A2 (en) 2008-03-20 2009-09-24 United States Department Of The Army, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research Carrier neutralization assay
SI3260136T1 (sl) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
WO2011109511A2 (en) * 2010-03-02 2011-09-09 International Aids Vaccine Initiative Novel hiv-1 envelope glycoprotein
EP2492279A1 (en) 2011-02-25 2012-08-29 Laboratorios Del. Dr. Esteve, S.A. Rapid immunogen selection method using lentiviral display

Also Published As

Publication number Publication date
AU2012219418B2 (en) 2017-05-25
CA2827967A1 (en) 2012-08-30
AU2012219418C1 (en) 2017-10-05
RS56707B1 (sr) 2018-03-30
PL2678351T3 (pl) 2018-03-30
JP2015508279A (ja) 2015-03-19
JP6140614B2 (ja) 2017-05-31
EP2678351B1 (en) 2017-09-13
EP2492279A1 (en) 2012-08-29
MX2013009757A (es) 2013-12-02
KR20140025356A (ko) 2014-03-04
RU2013143295A (ru) 2015-03-27
ME03045B (me) 2018-10-20
CN103459410B (zh) 2016-05-25
PT2678351T (pt) 2017-12-11
NZ614753A (en) 2015-10-30
IL228094A0 (en) 2013-09-30
EP2678351A1 (en) 2014-01-01
CN103459410A (zh) 2013-12-18
LT2678351T (lt) 2018-01-25
AU2012219418A1 (en) 2013-09-19
DK2678351T3 (en) 2017-12-04
CY1119638T1 (el) 2018-04-04
ES2651124T3 (es) 2018-01-24
US20140037667A1 (en) 2014-02-06
SI2678351T1 (en) 2018-01-31
HUE035432T2 (en) 2018-05-02
RU2603732C2 (ru) 2016-11-27
US9605030B2 (en) 2017-03-28
WO2012113921A1 (en) 2012-08-30
MX348459B (es) 2017-06-14

Similar Documents

Publication Publication Date Title
HRP20171697T1 (hr) Varijanta hiv gp-120
Plotkin Complex correlates of protection after vaccination
CY1124043T1 (el) Εξουδετερωτικα αντισωματα του ανθρωπινου ιου της ανοσοανεπαρκειας και μεθοδοι χρησης αυτων
EA201891415A8 (ru) Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения
PH12018500199A1 (en) Antibodies that potently neutralize hepatitis b virus and uses thereof
JP2015524422A5 (hr)
EA201300135A1 (ru) Комбинированная фармацевтическая композиция и способы лечения и профилактики инфекционных заболеваний
MX346475B (es) Peptidos inmunogenicos monomericos y multimericos.
HRP20161556T1 (hr) Virusna čestica otpuštena nakon infekcije sisavačkih stanica ljudskim citomegalovirusom (hcmv) koji sadrži fuzijski protein i njezina upotreba
Wang et al. A highly immunogenic fragment derived from Zaire Ebola virus glycoprotein elicits effective neutralizing antibody
PH12015501378A1 (en) Porcine parvovirus 5a, methods of use and vaccine
EA201290956A1 (ru) Вакцина против вич
PH12015501721A1 (en) Porcine parvovirus 5b, methods of use and vaccine
Bhide et al. Cross-protective potential and protection-relevant immune mechanisms of whole inactivated influenza virus vaccines are determined by adjuvants and route of immunization
WO2011082422A3 (en) Human immunodeficiency virus (hiv-1) highly conserved and low variant sequences as targets for vaccine and diagnostic applications
EA201592298A1 (ru) Полуживая вирусная вакцина против респираторно-синцитиального вируса
WO2018066999A3 (en) Chimeric enterovirus virus-like particles
RU2012130551A (ru) Штамм вируса гриппа а/17/виктория/2011/89 (h3n2) для производства живой гриппозной интраназальной вакцины для взрослых и для детей
EA201592299A1 (ru) Полуживая вирусная вакцина против респираторно-синцитиального вируса
RU2017110225A (ru) Способ получения вакцинных антигенов, получаемые вакцинные антигены и их применение
MX354571B (es) Genomas lentivirales quimericos no integrativos como vacunas innovadoras contra el virus de la inmunodeficiencia humana tipo 1 (vih-1).
EA201401044A1 (ru) Модифицированный вирус болезни марека и вакцины на его основе
Chen et al. Immunoprotective effect of inactivated coxsackievirus A16 vaccine in mice
CU20150019A7 (es) Rotavirus humanos modificados
Sambhara et al. H5N1 vaccine hits the target, but not the bull's eye